Use of personalized cancer drugs runs ahead of science...

And here's what a Harvard educated integrative oncologist, Brian Lewanda, MD, commented on this article:

"Using molecular and genetic assays to pick cancer drugs 'personalized' to each patient is not proving to be a home run. I wish we could compare this flawed, yet widely adopted approach, against my favorite chemosensitivity functional assay (EVA-PCD.) The vast majority of cancers are too heterogeneous and complex to be outsmarted by an assay-directed approach that isn't focusing on the most important question: "which drug(s) kill this cancer the most?" The EVA-PCD assay answers that question.

Has anyone had the EVA-PCD? If so, I'd be very interested to know how it worked for you.